Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Daiichi Sankyo Company ( (JP:4568) ) has provided an announcement.
The U.S. Federal Circuit Court of Appeals has vacated a previous infringement judgment and damages award against Daiichi Sankyo in a patent dispute with Seagen Inc. This decision nullifies the earlier ruling by the U.S. District Court for the Eastern District of Texas and dismisses Seagen’s appeal regarding the invalidation of their patent claims, positively impacting Daiichi Sankyo’s legal standing.
The most recent analyst rating on (JP:4568) stock is a Buy with a Yen4217.00 price target. To see the full list of analyst forecasts on Daiichi Sankyo Company stock, see the JP:4568 Stock Forecast page.
More about Daiichi Sankyo Company
Daiichi Sankyo is a global healthcare company with over 120 years of experience, focusing on discovering, developing, and delivering innovative medicines for cancer, cardiovascular, and other diseases with high unmet medical needs.
Average Trading Volume: 6,463,059
Technical Sentiment Signal: Hold
Current Market Cap: Yen7116.9B
For a thorough assessment of 4568 stock, go to TipRanks’ Stock Analysis page.